Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate
Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate
Orchestra BioMed Hldgs第一季度每股收益美元（0.38美元）超過預期（0.41美元），銷售額爲62萬美元，低於預期的940.00萬美元
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $620.00 thousand which missed the analyst consensus estimate of $940.00 thousand by 34.04 percent. This is a 46.74 percent decrease over sales of $1.16 million the same period last year.
Orchestra BioMed Hldgs（納斯達克股票代碼：OBIO）公佈的季度虧損爲每股0.38美元，比分析師普遍預期的0.41美元（0.41美元）高出7.32％。這比去年同期每股虧損0.40美元（0.40）增長了5％。該公司公佈的季度銷售額爲62萬美元，比分析師普遍預期的94萬美元低34.04％。這比去年同期的116萬美元銷售額下降了46.74％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。